Flag of the European Union EU Clinical Trials Register Help

Clinical trials for this compound hydrochloride

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44366   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: this compound hydrochloride. Displaying page 1 of 1.
    EudraCT Number: 2013-001966-40 Sponsor Protocol Number: CD001 Start Date*: 2014-01-27
    Sponsor Name:Companion Diagnostics BV
    Full Title: A double blind, randomized, placebo controlled, cross-over, Lybridos dose finding study to validate the predictive power of the diagnostic model for Lybrido and Lybridos efficacy and to identify an...
    Medical condition: Hypoactive Sexual Desire Disorder/SSRI-induced sexual dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10040470 Sexual desire disorders HLT
    14.1 100000004873 10020933 Hypoactive sexual desire disorder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004269-14 Sponsor Protocol Number: HP002-001 Start Date*: 2018-05-07
    Sponsor Name:Hamlet Pharma AB
    Full Title: A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery
    Medical condition: Non-muscle invasive bladder cancer awaiting transurethral surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003839-38 Sponsor Protocol Number: BAY1067197/15128 Start Date*: 2017-03-09
    Sponsor Name:Bayer AG
    Full Title: A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral parti...
    Medical condition: chronic heart failure with reduced ejection fraction (LVEF equal or below 35%)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004062-26 Sponsor Protocol Number: BAY1067197/17582 Start Date*: 2017-04-06
    Sponsor Name:Bayer AG
    Full Title: A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral parti...
    Medical condition: chronic heart failure with preserved ejection fraction (LVEF equal or above 45%)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) BG (Completed) PT (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000627-42 Sponsor Protocol Number: BCX1777-Bi-04-106 Start Date*: 2006-05-23
    Sponsor Name:BioCryst Pharmaceuticals Inc.
    Full Title: A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydr...
    Medical condition: B-cell acute lymphoblastic leukemia (B-ALL), which under WHO Guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036523 hlgt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004286-15 Sponsor Protocol Number: BCX1777-T-04-201 Start Date*: 2005-04-12
    Sponsor Name:BioCryst Pharmaceuticals Inc.
    Full Title: A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride Use
    Medical condition: Advanced T-cell Leukaemia (either precursor T-Lymphoblastic Leukaemia/Lymphoma or T-cell Prolymphocytic Leukaemia [T-PLL]).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10024324 hlgt
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000302-12 Sponsor Protocol Number: BUC-CLIN-303 Start Date*: 2016-07-13
    Sponsor Name:ARCA biopharma, Inc.
    Full Title: GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) PL (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003464-22 Sponsor Protocol Number: CEFTOFBN3004 Start Date*: 2007-10-05
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Noninferiority, Multicenter Study of Ceftobiprole Medocaril Versus Cefepime With or Without Vancomycin in the Treatment of Subjects Wi...
    Medical condition: Subjects 18 years of age or older with fever and neutropenia after chemotherapy for cancer, who require i.v. therapy for treatment of fever and neutropenia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002378-19 Sponsor Protocol Number: CLN-PXT3003-02 Start Date*: 2015-08-27
    Sponsor Name:PHARNEXT
    Full Title: International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-T...
    Medical condition: Charcot-Marie-Tooth Disease - Type 1A
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Suspended by CA) ES (Completed) BE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001999-67 Sponsor Protocol Number: DRI10566 Start Date*: 2009-01-30
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de 14 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de Nerispirdina 50 mg, 100 mg y 200...
    Medical condition: Esclerosis Múltiple ______________ Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    11.0 10028245 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000509-31 Sponsor Protocol Number: 206-OC-202 Start Date*: 2007-10-10
    Sponsor Name:Biogen Idec Ltd
    Full Title: Estudio en fase 1/2, abierto, adaptativo, aleatorio de doxorrubicina liposómica con o sin M200 (volociximab) para el tratamiento de pacientes con cáncer de ovario epitelial avanzado o cáncer perito...
    Medical condition: Cáncer de ovario epitelial avanzado o cáncer peritoneal primario Advanced epithelial ovarian cancer or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003080-38 Sponsor Protocol Number: GOAT_1-2_1407 Start Date*: 2015-06-26
    Sponsor Name: Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour
    Full Title: Glutamatergic medication in the treatment of Obsessive Compulsive Disorder (OCD) and Autism Spectrum Disorder (ASD)
    Medical condition: - Obsessive-compulsive disorder - Autistic Diorder, Aspergers' Disorder, PDD NOS
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-001861-40 Sponsor Protocol Number: BRTA-0100-015 (EORTC 62061) Start Date*: 2006-09-21
    Sponsor Name:SYSTEMS MEDICINE, LLC
    Full Title: Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
    Medical condition: Advanced or metastatic soft tissue sarcoma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001503-31 Sponsor Protocol Number: RD.03.SPR.105078 Start Date*: 2015-11-30
    Sponsor Name:Galderma R&D
    Full Title: Subject adherence and satisfaction for treatment of Onychomycosis with Loceryl® Nail Lacquer 5% versus Canesten® Fungal Nail Treatment Set
    Medical condition: Mycological confirmed toenail Distal and Lateral Subungual Onychomycosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10030338 Onychomycosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2012-005138-12 Sponsor Protocol Number: BRCAP-GELTAMO12 Start Date*: 2013-03-26
    Sponsor Name:GELTAMO (Grupo Cooperativo Español de Linfoma/Trasplante Autólogo de Médula Ósea)
    Full Title: Randomized phase II study of treatment with R-CHOP vs Bortezomib-R-CAP for young patients with poor IPI diffuse large B-cell lymphoma.
    Medical condition: Diffuse large B cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002379-81 Sponsor Protocol Number: CLN-PXT3003-03 Start Date*: 2017-01-26
    Sponsor Name:Pharnext
    Full Title: International, multi-center, double blind 9-month FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.
    Medical condition: Charcot-Marie-Tooth Disease type 1A
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Suspended by CA) BE (Completed) NL (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-007444-34 Sponsor Protocol Number: SYR-322_305 Start Date*: 2009-06-29
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in...
    Medical condition: Patients with type II diabetes mellitus (T2DM) who are currently treated with a stable daily dose of metformin alone but experiencing inadequate glycemic control
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LT (Completed) LV (Completed) AT (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Dec 28 01:11:34 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA